Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Beijing Biotech clinical trials
The registry lists 32 studies whose lead sponsor is Beijing Biotech. 32 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 4, 2026.
Keep track of what changes. Save the Beijing Biotech studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Beijing Biotech.
- Beijing Biotech32 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 32 of 32.
- Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)RecruitingNCT07744256Phase 1/2
- Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLCRecruitingNCT07641023Phase 1/2
- Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate CancerRecruitingNCT07641049Phase 1
- Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract CancerRecruitingNCT07641036Phase 1/2
- Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced MelanomaRecruitingNCT07627698Phase 1/2
- Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal AdenocarcinomaRecruitingNCT07627711Phase 1/2
- Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal AdenocarcinomaRecruitingNCT07622940Phase 1/2
- EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCCRecruitingNCT07617805Phase 1/2
- Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2RecruitingNCT07617753Phase 1/2
- Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic CarcinomaRecruitingNCT07598955Phase 1/2
- Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian CancerRecruitingNCT07589543Phase 1/2
- Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid TumorsRecruitingNCT07589530Phase 1/2
- Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal CancerRecruitingNCT07589517Phase 1/2
- Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ CancerRecruitingNCT07551362Phase 1/2
- Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell CarcinomaRecruitingNCT07551349Phase 1/2
- Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade GliomaRecruitingNCT07551336Phase 1
- Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid TumorsRecruitingNCT07523529Phase 1/2
- SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory LupusRecruitingNCT07523542Phase 1/2
- Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic MalignanciesRecruitingNCT07523555Phase 1/2
- Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal MesotheliomaRecruitingNCT07510815Phase 1/2
- PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid TumorsRecruitingNCT07510828Phase 1/2
- Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBCRecruitingNCT07510802Phase 1/2
- Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCCRecruitingNCT07500220Phase 1/2
- Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory NeuroblastomaRecruitingNCT07502287Phase 1/2
- Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial CarcinomaRecruitingNCT07492628Phase 1
- Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)RecruitingNCT07486089Phase 1/2
- Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade GliomaRecruitingNCT07480941Phase 1
- Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)RecruitingNCT07480213Phase 1/2
- Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)RecruitingNCT07480954Phase 1/2
- Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal AdenocarcinomaRecruitingNCT07480928Phase 1/2
- Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLCRecruitingNCT07467863Phase 1/2
- Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal CancerRecruitingNCT07462650Phase 1/2